RecentMedicalFindings.com
Summarizing relevant biomedical research!
polypharmacy     Bookmark and Share
Search webpages of this site (RecentMedicalFindings):
Didn't find what you wanted? Try it at BioMedLib™ !
Search directly on the biomedical articles using BioMedLib™ search engine:



1. Biomedical articles (top 50; 2009 to 2014)
1. |||||||||. 100%  Ballon J, Stroup TS: Polypharmacy for schizophrenia. Curr Opin Psychiatry; 2013 Mar;26(2):208-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy for schizophrenia.
  • This review provides an update on evidence regarding the effectiveness of polypharmacy approaches.
  • RECENT FINDINGS: Epidemiology studies have demonstrated that polypharmacy is extremely common, but evidence regarding all polypharmacy approaches for schizophrenia from randomized controlled trials remains scarce.
  • [MeSH-major] Antidepressive Agents / therapeutic use. Antipsychotic Agents / therapeutic use. Benzodiazepines / therapeutic use. Polypharmacy. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1209-23 [16172203.001]
  • [Cites] Schizophr Bull. 2003;29(3):531-40 [14609246.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005962 [17054266.001]
  • [Cites] Acta Psychiatr Scand. 2007 Feb;115(2):101-5 [17244173.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD006391 [17253592.001]
  • [Cites] Schizophr Res. 2007 May;92(1-3):68-73 [17336500.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD001258 [17636660.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD003834 [17636738.001]
  • [Cites] Fundam Clin Pharmacol. 2008 Jun;22(3):323-33 [18485151.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(3):CD004028 [18646098.001]
  • [Cites] Schizophr Bull. 2009 Mar;35(2):443-57 [18417466.001]
  • [Cites] J Clin Psychiatry. 2009 Jul;70(7):1041-50 [19653979.001]
  • [Cites] Schizophr Bull. 2010 Jan;36(1):71-93 [19955390.001]
  • [Cites] Schizophr Res. 2010 May;118(1-3):218-23 [20207521.001]
  • [Cites] Psychiatry Res. 2010 Aug 30;179(1):19-23 [20472299.001]
  • [Cites] Int J Neuropsychopharmacol. 2010 Sep;13(8):1115-25 [20459883.001]
  • [Cites] Br J Psychiatry. 2010 Sep;197(3):174-9 [20807960.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):208-11 [21095214.001]
  • [Cites] Br J Clin Pharmacol. 2011 Mar;71(3):377-82 [21284696.001]
  • [Cites] Schizophr Res. 2011 Apr;127(1-3):93-9 [21262565.001]
  • [Cites] J Clin Psychiatry. 2011 Mar;72(3):326-30 [20816037.001]
  • [Cites] J Psychopharmacol. 2011 May;25(5):667-74 [20615930.001]
  • [Cites] J Clin Psychopharmacol. 2011 Jun;31(3):266-73 [21508849.001]
  • [Cites] Am J Psychiatry. 2011 Jul;168(7):702-8 [21536693.001]
  • [Cites] Psychiatr Serv. 2011 Aug;62(8):908-14 [21807830.001]
  • [Cites] BMC Psychiatry. 2011;11:118 [21791046.001]
  • [Cites] Int Clin Psychopharmacol. 2011 Nov;26(6):311-5 [21849905.001]
  • [Cites] Int Clin Psychopharmacol. 2011 Nov;26(6):303-10 [21934625.001]
  • [Cites] Eur Neuropsychopharmacol. 2012 Mar;22(3):165-82 [21906915.001]
  • [Cites] J Clin Psychopharmacol. 2012 Apr;32(2):165-72 [22367654.001]
  • [Cites] Arch Gen Psychiatry. 2012 May;69(5):476-83 [22566579.001]
  • [Cites] Expert Opin Drug Saf. 2012 Jul;11(4):527-42 [22563628.001]
  • [Cites] Acta Psychiatr Scand. 2002 Nov;106(5):323-30 [12366465.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(2):CD002305 [12076447.001]
  • [Cites] Nature. 2011 Jun 16;474(7351):277-8 [21677725.001]
  • [Cites] Neuropsychopharmacology. 2003 Jan;28(1):182-92 [12496955.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD005581 [16856105.001]
  • (PMID = 23318662.001).
  • [ISSN] 1473-6578
  • [Journal-full-title] Current opinion in psychiatry
  • [ISO-abbreviation] Curr Opin Psychiatry
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / KM1 CA156709; United States / NCI NIH HHS / CA / KM1 CA156709
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antipsychotic Agents; 12794-10-4 / Benzodiazepines
  • [Other-IDs] NLM/ NIHMS574232; NLM/ PMC4026924
  •  go-up   go-down


2. ||||||||.. 83%  Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, Iwasaki W, Masaki K: Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Dir Assoc; 2012 Nov;13(9):818.e11-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing cost by reducing polypharmacy: the polypharmacy outcomes project.
  • OBJECTIVE: To examine the effect of intervention by geriatric medicine fellows and a geriatrician on medication cost among long term care residents with polypharmacy.
  • PARTICIPANTS: Long term care residents with polypharmacy, defined as being on 9 or more medications.
  • CONCLUSION: This polypharmacy reduction intervention by physicians used readily available tools, demonstrated a significant decrease in medication-related costs, and provided training in the core competencies of practice-based learning and improvement and systems-based practice to geriatric medicine fellows in long term care.
  • [MeSH-major] Nursing Homes / economics. Polypharmacy

  • MedlinePlus Health Information. consumer health - Nursing Homes.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 American Medical Directors Association, Inc. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Nutr Health Aging. 1997;1(3):181-4 [10995088.001]
  • [Cites] Geriatr Gerontol Int. 2012 Jul;12(3):425-30 [22212467.001]
  • [Cites] J Am Geriatr Soc. 2002 Dec;50(12):1962-8 [12473007.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2716-24 [14662625.001]
  • [Cites] Health Serv Res. 2004 Oct;39(5):1257-76 [15333108.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1825-32 [1888249.001]
  • [Cites] Ann Intern Med. 1995 Aug 1;123(3):195-204 [7598302.001]
  • [Cites] Int J Geriatr Psychiatry. 1998 Jul;13(7):433-9 [9695030.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):68-74 [15642877.001]
  • [Cites] Am J Geriatr Pharmacother. 2004 Dec;2(4):248-56 [15903283.001]
  • [Cites] J Manag Care Pharm. 2005 Sep;11(7):575-83 [16137215.001]
  • [Cites] Am J Geriatr Pharmacother. 2006 Mar;4(1):36-41 [16730619.001]
  • [Cites] J Am Med Dir Assoc. 2007 Mar;8(3):173-7 [17349946.001]
  • [Cites] Isr Med Assoc J. 2007 Jun;9(6):430-4 [17642388.001]
  • [Cites] QJM. 2007 Nov;100(11):691-7 [17932098.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Feb;8(1):63-72 [20226393.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):901-10 [20623513.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Dec;8(6):562-70 [21356505.001]
  • [Cites] J Am Med Dir Assoc. 2011 Jun;12(5):326-30 [21450207.001]
  • [Cites] J Am Med Dir Assoc. 2012 Mar;13(3):309.e15-21 [21839687.001]
  • [Cites] J Am Geriatr Soc. 2012 Apr;60(4):616-31 [22376048.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):199-216 [22500539.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):217-36 [22500540.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):237-53 [22500541.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):323-41 [22500546.001]
  • [Cites] Clin Geriatr Med. 2012 May;28(2):xiii-xiv [22500547.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2012 Jun;67(6):698-704 [22219520.001]
  • [Cites] Arch Intern Med. 2001 Jul 9;161(13):1629-34 [11434795.001]
  • (PMID = 22959733.001).
  • [ISSN] 1538-9375
  • [Journal-full-title] Journal of the American Medical Directors Association
  • [ISO-abbreviation] J Am Med Dir Assoc
  • [Language] eng
  • [Grant] United States / PHS HHS / / 1K01HP20503; United States / NCRR NIH HHS / RR / 1R25RR019321; United States / NCRR NIH HHS / RR / R25 RR019321
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS398979; NLM/ PMC3489959
  •  go-up   go-down


3. |||||||... 73%  Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH, Schizophrenia Trials Network: Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry; 2011 Jul;168(7):702-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
  • OBJECTIVE: This randomized trial addressed the risks and benefits of staying on antipsychotic polypharmacy or switching to monotherapy.
  • METHOD: Adult outpatients with schizophrenia taking two antipsychotics (127 participants across 19 sites) were randomly assigned to stay on polypharmacy or switch to monotherapy by discontinuing one antipsychotic.
  • RESULTS: Patients assigned to switch to monotherapy had shorter times to all-cause treatment discontinuation than those assigned to stay on polypharmacy.
  • By month 6, 86% (N=48) of those assigned to stay on polypharmacy were still taking both medications, whereas 69% (N=40) of those assigned to switch to monotherapy were still taking the same medication.
  • Most monotherapy discontinuations entailed returning to the original polypharmacy.
  • On average, the monotherapy group lost weight, whereas the polypharmacy group gained weight.
  • These results support the reasonableness of prescribing guidelines encouraging trials of antipsychotic monotherapy for individuals receiving antipsychotic polypharmacy, with the caveat that patients should be free to return to polypharmacy if an adequate trial on antipsychotic monotherapy proves unsatisfactory.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Polypharmacy. Schizophrenia / drug therapy
  • [MeSH-minor] Adolescent. Adult. Diagnostic and Statistical Manual of Mental Disorders. Drug Administration Schedule. Drug Therapy, Combination. Female. Humans. Longitudinal Studies. Male. Proportional Hazards Models. Psychiatric Status Rating Scales. Psychotic Disorders / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. See the articles recommended by F1000Prime's Faculty of more than 5,000 expert scientists and clinical researchers. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychopharmacol Bull. 1988;24(4):603-7 [3074321.001]
  • [Cites] J Clin Psychiatry. 1997 Dec;58(12):538-46 [9448657.001]
  • [Cites] Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56 [15000267.001]
  • [Cites] Br J Psychiatry. 1997 Dec;171:569-73 [9519099.001]
  • [Cites] Am J Psychiatry. 2005 Jan;162(1):130-6 [15625211.001]
  • [Cites] J Clin Psychiatry. 2005 Jan;66(1):63-72 [15669890.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1209-23 [16172203.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):472-82 [16452559.001]
  • [Cites] Am J Psychiatry. 2006 Dec;163(12):2090-5 [17151159.001]
  • [Cites] Schizophr Res. 2007 May;92(1-3):90-4 [17321111.001]
  • [Cites] Schizophr Bull. 2009 Mar;35(2):443-57 [18417466.001]
  • [Cites] Psychiatr Serv. 2009 Dec;60(12):1595-602 [19952148.001]
  • [Cites] Schizophr Bull. 2010 Jan;36(1):71-93 [19955390.001]
  • [Cites] Biol Psychiatry. 2010 Feb 1;67(3):255-62 [19897178.001]
  • [Cites] Am J Psychiatry. 2010 Jun;167(6):686-93 [20360319.001]
  • [Cites] J Clin Psychiatry. 2004 Apr;65(4):500-8 [15119912.001]
  • [Cites] Int J Neuropsychopharmacol. 2004 Jun;7(2):133-42 [14741059.001]
  • [Cites] Am J Psychiatry. 2004 Aug;161(8):1334-49 [15285957.001]
  • [Cites] J Clin Psychiatry. 2004 Oct;65(10):1377-88 [15491242.001]
  • [Cites] Acta Psychiatr Scand Suppl. 1970;212:11-9 [4917967.001]
  • [Cites] Arch Gen Psychiatry. 1982 Apr;39(4):486-7 [6121550.001]
  • [Cites] Schizophr Bull. 1987;13(2):261-76 [3616518.001]
  • [Cites] J Sex Marital Ther. 2000 Jan-Mar;26(1):25-40 [10693114.001]
  • [Cites] Schizophr Bull. 2002;28(1):75-84 [12047024.001]
  • [Cites] Am J Psychiatry. 2002 Nov;159(11):1932-5 [12411232.001]
  • [Cites] Psychiatr Serv. 2003 Jan;54(1):55-9 [12509667.001]
  • [Cites] Am J Psychiatry. 2003 Jun;160(6):1125-32 [12777271.001]
  • [CommentIn] Am J Psychiatry. 2011 Oct;168(10):1117; author reply 1117 [21969048.001]
  • [CommentIn] Am J Psychiatry. 2011 Jul;168(7):667-9 [21724670.001]
  • (PMID = 21536693.001).
  • [ISSN] 1535-7228
  • [Journal-full-title] The American journal of psychiatry
  • [ISO-abbreviation] Am J Psychiatry
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00044655
  • [Grant] United States / NIMH NIH HHS / MH / MH59312; United States / NIMH NIH HHS / MH / MH900001; United States / NIMH NIH HHS / MH / N01MH90001; United States / NIMH NIH HHS / MH / R01 MH059312
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Other-IDs] NLM/ NIHMS494901; NLM/ PMC3739691
  • [Investigator] Adler L; Byerly M; Caroff S; Csernansky J; D'Souza C; Jackson C; Peters JJ; Manschreck T; McEvoy J; Miller A; Nasrallah H; Olson S; Patel J; Saltz B; Steinbook RM; Tapp A; Marcus K
  •  go-up   go-down


Advertisement
4. |||||||... 71%  Dussias P, Kalali AH, Citrome L: Polypharmacy of schizophrenia. Psychiatry (Edgmont); 2010 Aug;7(8):17-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy of schizophrenia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20877529.001).
  • [ISSN] 1555-5194
  • [Journal-full-title] Psychiatry (Edgmont (Pa. : Township))
  • [ISO-abbreviation] Psychiatry (Edgmont)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2945852
  • [Keywords] NOTNLM ; Schizophrenia / antidepressants / antipsychotics / extrapyramidal symptoms / mood stabilizers
  •  go-up   go-down


5. |||||||... 67%  Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU: Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf; 2012 Jul;11(4):527-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and tolerability of antipsychotic polypharmacy.
  • INTRODUCTION: Antipsychotic polypharmacy (APP), the concomitant use of ≥ 2 antipsychotics, is common in clinical practice.
  • [MeSH-major] Antipsychotic Agents / adverse effects. Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Nerv Syst. 1977 Jul;38(7):541-5 [17517.001]
  • [Cites] Psychopharmacology (Berl). 1986;88(4):403-19 [2871578.001]
  • [Cites] Br J Psychiatry. 1987 Jan;150:88-91 [3115352.001]
  • [Cites] Psychiatry Res. 1991 Jun;37(3):297-308 [1679950.001]
  • [Cites] Br J Psychiatry Suppl. 1992 May;(17):54-9 [1358128.001]
  • [Cites] Br J Clin Pharmacol. 1995 Nov;40(5):467-76 [8703651.001]
  • [Cites] J Clin Psychopharmacol. 1997 Aug;17(4):314-7 [9241012.001]
  • [Cites] Br J Psychiatry. 1997 Dec;171:569-73 [9519099.001]
  • [Cites] Am J Psychiatry. 1998 Sep;155(9):1207-13 [9734544.001]
  • [Cites] J Clin Psychiatry. 1996 Sep;57(9):395-7 [9746446.001]
  • [Cites] Br J Psychiatry. 1998 Oct;173:325-9 [9926037.001]
  • [Cites] Schizophr Res. 1999 Mar 1;35 Suppl:S67-73 [10190227.001]
  • [Cites] Actas Esp Psiquiatr. 2004 Nov-Dec;32(6):333-9 [15529221.001]
  • [Cites] J Clin Psychiatry. 2004 Nov;65(11):1491-8 [15554761.001]
  • [Cites] J Clin Psychiatry. 2005 Jan;66(1):63-72 [15669890.001]
  • [Cites] Aust N Z J Psychiatry. 2005 Sep;39(9):840-1 [16168043.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1209-23 [16172203.001]
  • [Cites] Clin Neuropharmacol. 2005 Sep-Oct;28(5):220-4 [16239761.001]
  • [Cites] Drug Metab Pharmacokinet. 2005 Oct;20(5):368-78 [16272755.001]
  • [Cites] Ann Pharmacother. 2010 Jul-Aug;44(7-8):1171-80 [20587746.001]
  • [Cites] Eur Psychiatry. 2010 Jun;25 Suppl 2:S12-21 [20620881.001]
  • [Cites] Int J Neuropsychopharmacol. 2010 Sep;13(8):1115-25 [20459883.001]
  • [Cites] Pharmacopsychiatry. 2010 Aug;43(6):216-20 [20589598.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1333-41 [20691745.001]
  • [Cites] J Clin Psychopharmacol. 2010 Oct;30(5):518-25 [20814315.001]
  • [Cites] J Clin Psychopharmacol. 2010 Oct;30(5):596-9 [20814333.001]
  • [Cites] Br J Psychiatry. 2010 Oct;197(4):266-71 [20884948.001]
  • [Cites] Acta Psychiatr Scand. 2010 Nov;122(5):356-66 [20528803.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1495-9 [20732372.001]
  • [Cites] Aust N Z J Psychiatry. 2011 Jan;45(1):89 [21058927.001]
  • [Cites] Trends Mol Med. 2011 Feb;17(2):97-107 [21185230.001]
  • [Cites] J Clin Psychiatry. 2011 Feb;72(2):240-7 [20868629.001]
  • [Cites] Am J Psychiatry. 2011 Jul;168(7):702-8 [21536693.001]
  • [Cites] BMC Psychiatry. 2011;11:118 [21791046.001]
  • [Cites] Schizophr Res. 2011 Sep;131(1-3):58-62 [21419603.001]
  • [Cites] Nord J Psychiatry. 2011 Oct;65(5):345-52 [21428861.001]
  • [Cites] Eur J Health Econ. 2012 Jun;13(3):355-63 [21452062.001]
  • [Cites] Schizophr Res. 2012 Jun;138(1):18-28 [22534420.001]
  • [Cites] Eur J Clin Pharmacol. 1999 Nov;55(9):685-90 [10638400.001]
  • [Cites] Drug Saf. 2000 Jan;22(1):73-81 [10647977.001]
  • [Cites] J Clin Psychiatry. 2000;61 Suppl 4:5-9 [10739324.001]
  • [Cites] Ann Pharmacother. 2000 May;34(5):662-5 [10852096.001]
  • [Cites] Drug Saf. 2000 Sep;23(3):215-28 [11005704.001]
  • [Cites] Can J Psychiatry. 2001 May;46(4):334-9 [11387789.001]
  • [Cites] J Clin Psychiatry. 2001 Aug;62(8):605-8 [11561931.001]
  • [Cites] J Clin Psychiatry. 2001;62 Suppl 23:23-9 [11603882.001]
  • [Cites] J Clin Psychiatry. 2002 Feb;63(2):93-4 [11874226.001]
  • [Cites] Br J Psychiatry. 2003 Mar;182:199-204 [12611781.001]
  • [Cites] J Clin Psychopharmacol. 2003 Jun;23(3 Suppl 1):S21-6 [12832946.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):361-9 [14751434.001]
  • [Cites] Am J Psychiatry. 2004 Apr;161(4):700-6 [15056517.001]
  • [Cites] Br J Clin Pharmacol. 2004 Aug;58(2):178-83 [15255800.001]
  • [Cites] J Psychiatr Pract. 2007 Mar;13(2):129-37 [17414692.001]
  • [Cites] Psychiatr Serv. 2007 Apr;58(4):489-95 [17412850.001]
  • [Cites] Pharmacopsychiatry. 2007 Mar;40(2):47-52 [17447172.001]
  • [Cites] Am J Psychiatry. 2007 Jun;164(6):870-6 [17541044.001]
  • [Cites] Aust N Z J Psychiatry. 2007 Jul;41(7):606-10 [17558623.001]
  • [Cites] J Psychopharmacol. 2007 Jun;21(4):453-6 [17050662.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1255-60 [17600607.001]
  • [Cites] Psychiatry Res. 2007 Aug 30;152(2-3):165-72 [17445906.001]
  • [Cites] Am J Psychiatry. 2007 Sep;164(9):1404-10 [17728426.001]
  • [Cites] CNS Spectr. 2007 Sep;12(9 Suppl 14):1-13 [17805218.001]
  • [Cites] Compr Psychiatry. 2008 Jan-Feb;49(1):65-9 [18063043.001]
  • [Cites] Schizophr Res. 2008 Jan;98(1-3):323-4 [17950576.001]
  • [Cites] Hum Psychopharmacol. 2008 Jun;23(4):283-90 [18302312.001]
  • [Cites] J Psychopharmacol. 2008 May;22(3):244-53 [18308789.001]
  • [Cites] J Clin Psychiatry. 2008 May;69(5):720-31 [18370574.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2008 Oct;34(10):571-82 [18947117.001]
  • [Cites] N Engl J Med. 2009 Jan 15;360(3):225-35 [19144938.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2009 Feb;259(1):23-7 [18574608.001]
  • [Cites] Schizophr Bull. 2009 Mar;35(2):443-57 [18417466.001]
  • [Cites] Schizophr Bull. 2009 Mar;35(2):458-68 [18436527.001]
  • [Cites] Hum Psychopharmacol. 2009 Apr;24(3):225-32 [19283774.001]
  • [Cites] J Psychopharmacol. 2009 May;23(3):305-14 [18562423.001]
  • [Cites] Eur Neuropsychopharmacol. 2009 Jul;19(7):520-32 [19411165.001]
  • [Cites] J Clin Psychopharmacol. 2009 Apr;29(2):165-9 [19512978.001]
  • [Cites] Lancet. 2009 Aug 22;374(9690):620-7 [19595447.001]
  • [Cites] Am J Psychiatry. 2009 Sep;166(9):1055-62 [19570929.001]
  • [Cites] JAMA. 2009 Oct 28;302(16):1765-73 [19861668.001]
  • [Cites] J Clin Psychiatry. 2009 Oct;70(10):1348-57 [19906340.001]
  • [Cites] Br J Psychiatry. 2004 Aug;185:152-6 [15286067.001]
  • [Cites] Psychiatr Serv. 2004 Sep;55(9):1006-13 [15345760.001]
  • [Cites] J Clin Psychiatry. 2004 Oct;65(10):1377-88 [15491242.001]
  • [Cites] Int Clin Psychopharmacol. 2006 Mar;21(2):99-103 [16421461.001]
  • [Cites] J Clin Psychiatry. 2005 Nov;66(11):1386-91 [16420075.001]
  • [Cites] Acta Psychiatr Scand. 2006 Feb;113(2):135-41 [16423165.001]
  • [Cites] Acta Psychiatr Scand. 2006 Feb;113(2):142-7 [16423166.001]
  • [Cites] Br J Psychiatry. 2006 Feb;188:122-7 [16449697.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):472-82 [16452559.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1167-9 [16647796.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Aug 1;214(3):326-34 [16510162.001]
  • [Cites] Psychiatr Serv. 2006 Aug;57(8):1094-101 [16870959.001]
  • [Cites] Schizophr Res. 2006 Sep;86(1-3):138-46 [16793238.001]
  • [Cites] Int Clin Psychopharmacol. 2006 Nov;21(6):355-62 [17012982.001]
  • [Cites] Schizophr Res. 2007 Jan;89(1-3):91-100 [17070017.001]
  • [Cites] Curr Opin Psychiatry. 2007 Mar;20(2):138-42 [17278911.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3456-9 [17360666.001]
  • [Cites] Schizophr Res. 2010 Jan;116(1):35-43 [19892525.001]
  • [Cites] Curr Opin Psychiatry. 2010 Mar;23(2):103-11 [20051861.001]
  • [Cites] Curr Drug Saf. 2010 Jan;5(1):97-104 [20210726.001]
  • [Cites] J Clin Psychiatry. 2010 May;71(5):566-73 [20361903.001]
  • [Cites] J Psychopharmacol. 2010 Jul;24(7):1037-44 [19164494.001]
  • (PMID = 22563628.001).
  • [ISSN] 1744-764X
  • [Journal-full-title] Expert opinion on drug safety
  • [ISO-abbreviation] Expert Opin Drug Saf
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / P30 MH090590-03
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Other-IDs] NLM/ NIHMS369312; NLM/ PMC3384511
  •  go-up   go-down


6. ||||||.... 65%  Maggiore RJ, Gross CP, Hurria A: Polypharmacy in older adults with cancer. Oncologist; 2010;15(5):507-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in older adults with cancer.
  • The definition of "polypharmacy" ranges from the use of a large number of medications; the use of potentially inappropriate medications, which can increase the risk for adverse drug events; medication underuse despite instructions to the contrary; and medication duplication.
  • Cancer-related therapy adds to this risk in older adults, but few studies have been conducted in this patient population.
  • In this review, we outline the adverse outcomes associated with polypharmacy and present polypharmacy definitions offered by the geriatrics literature.
  • We also examine the strengths and weaknesses of these definitions and explore the relationships among these definitions and what is known about the prevalence and impact of polypharmacy.
  • [MeSH-major] Neoplasms / drug therapy. Polypharmacy

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 2006 Nov;54(11):1725-35 [17087700.001]
  • [Cites] Drugs Aging. 2006;23(11):915-24 [17109569.001]
  • [Cites] Am J Geriatr Pharmacother. 2004 Jun;2(2):92-101 [15555485.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4810-5 [15570083.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2642-8 [10594859.001]
  • [Cites] Acad Emerg Med. 1999 Dec;6(12):1232-42 [10609925.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 5;92(1):42-7 [10620632.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2000 Feb;55(2):M57-63 [10737686.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Oncol Nurs Forum. 2000 May;27(4):623-30 [10833691.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2505-14 [10893280.001]
  • [Cites] Arch Intern Med. 2000 Jul 24;160(14):2129-34 [10904455.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2000 Oct;55(10):M554-9 [11034227.001]
  • [Cites] J Altern Complement Med. 2000 Dec;6(6):531-8 [11152058.001]
  • [Cites] J Am Geriatr Soc. 2001 Feb;49(2):200-9 [11207875.001]
  • [Cites] Ann Pharmacother. 2001 May;35(5):539-45 [11346058.001]
  • [Cites] Am J Clin Nutr. 2001 Aug;74(2):201-5 [11470721.001]
  • [Cites] J Clin Epidemiol. 1994 Aug;47(8):891-6 [7730892.001]
  • [Cites] Can J Hosp Pharm. 1995 Jun;48(3):161-6 [10172367.001]
  • [Cites] Am J Med. 1996 Apr;100(4):428-37 [8610730.001]
  • [Cites] JAMA. 1997 Jan 8;277(2):115-21 [8990335.001]
  • [Cites] Ann Pharmacother. 1997 May;31(5):529-33 [9161643.001]
  • [Cites] Ann Pharmacother. 1997 May;31(5):543-8 [9161645.001]
  • [Cites] Arch Intern Med. 1997 Jul 28;157(14):1531-6 [9236554.001]
  • [Cites] Arch Intern Med. 1997 Aug 11-25;157(15):1681-6 [9250229.001]
  • [Cites] J Am Geriatr Soc. 1997 Aug;45(8):945-8 [9256846.001]
  • [Cites] Arch Intern Med. 1997 Oct 13;157(18):2089-96 [9382665.001]
  • [Cites] J Am Geriatr Soc. 1997 Nov;45(11):1360-1 [9361662.001]
  • [Cites] Dysphagia. 1998 Spring;13(2):69-81 [9513300.001]
  • [Cites] J Am Geriatr Soc. 1998 Jun;46(6):751-2 [9625192.001]
  • [Cites] Epidemiology. 1998 Jul;9(4):417-23 [9647906.001]
  • [Cites] J Am Geriatr Soc. 1998 Sep;46(9):1128-31 [9736107.001]
  • [Cites] Arch Intern Med. 1998 Oct 12;158(18):2024-8 [9778202.001]
  • [Cites] J Am Geriatr Soc. 1998 Nov;46(11):1423-4 [9809766.001]
  • [Cites] J Am Geriatr Soc. 1999 Jan;47(1):30-9 [9920227.001]
  • [Cites] J Am Geriatr Soc. 1999 Jan;47(1):40-50 [9920228.001]
  • [Cites] J Clin Pharm Ther. 1998 Dec;23(6):423-32 [10048503.001]
  • [Cites] N Engl J Med. 1999 Jun 3;340(22):1733-9 [10352166.001]
  • [Cites] Cancer Pract. 1999 May-Jun;7(3):136-44 [10352076.001]
  • [Cites] Drugs Aging. 2006;23(10):823-37 [17067185.001]
  • [Cites] Drugs Aging. 2008;25(11):947-54 [18947262.001]
  • [Cites] Integr Cancer Ther. 2008 Sep;7(3):122-9 [18956493.001]
  • [Cites] Pharm World Sci. 2006 Oct;28(5):296-301 [17111245.001]
  • [Cites] J Clin Pharm Ther. 2006 Dec;31(6):617-26 [17176367.001]
  • [Cites] Cancer Nurs. 2007 Jan-Feb;30(1):45-55; quiz 56-7 [17235219.001]
  • [Cites] Med Care. 2007 Jan;45(1):95-9 [17279026.001]
  • [Cites] Am J Geriatr Pharmacother. 2004 Dec;2(4):239-47 [15903282.001]
  • [Cites] Ann Pharmacother. 2007 Mar;41(3):438-47 [17311835.001]
  • [Cites] BMC Med Inform Decis Mak. 2007;7:7 [17346336.001]
  • [Cites] J Clin Pharm Ther. 2007 Apr;32(2):169-75 [17381667.001]
  • [Cites] Support Care Cancer. 2007 May;15(5):557-64 [17205277.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):592-600 [17440160.001]
  • [Cites] J Am Geriatr Soc. 2007 May;55(5):658-65 [17493184.001]
  • [Cites] J Support Oncol. 2007 Apr;5(4):195-8 [17500507.001]
  • [Cites] Pharm World Sci. 2007 Jun;29(3):109-15 [17353970.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):658-67 [16906628.001]
  • [Cites] J Altern Complement Med. 2007 Jun;13(5):555-62 [17604560.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Mar;5(1):40-7 [17608246.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Jun;5(2):147-61 [17719517.001]
  • [Cites] Am J Emerg Med. 2007 Sep;25(7):804-7 [17870486.001]
  • [Cites] Ann Pharmacother. 2007 Oct;41(10):1617-24 [17785609.001]
  • [Cites] Ann Pharmacother. 2001 Sep;35(9):1004-9 [11573845.001]
  • [Cites] J Intern Med. 2001 Oct;250(4):327-41 [11576320.001]
  • [Cites] Oncology (Williston Park). 2001 Oct;15(10):1267-72; discussion 1272-8, 1283 [11702957.001]
  • [Cites] JAMA. 2001 Dec 12;286(22):2823-9 [11735757.001]
  • [Cites] Med Care. 2002 Feb;40(2):166-76 [11802089.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):363-7 [11855870.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1187-8 [12189216.001]
  • [Cites] J Altern Complement Med. 2002 Aug;8(4):477-85 [12230908.001]
  • [Cites] Am J Public Health. 2002 Oct;92(10):1606-9 [12356606.001]
  • [Cites] J Altern Complement Med. 2002 Oct;8(5):661-71 [12470448.001]
  • [Cites] J Am Geriatr Soc. 2002 Dec;50(12):1962-8 [12473007.001]
  • [Cites] Ann Pharmacother. 2003 Jan;37(1):40-6 [12503931.001]
  • [Cites] J Urol. 2003 Jul;170(1):166-9 [12796672.001]
  • [Cites] Drugs Aging. 2003;20(10):769-76 [12875612.001]
  • [Cites] Arch Intern Med. 2003 Oct 13;163(18):2165-72 [14557214.001]
  • [Cites] BMC Complement Altern Med. 2002 Aug 13;2:8 [12175424.001]
  • [Cites] Ann Intern Med. 2003 Nov 4;139(9):740-7 [14597458.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2716-24 [14662625.001]
  • [Cites] Altern Ther Health Med. 2004 Jan-Feb;10(1):52-7 [14727500.001]
  • [Cites] Ann Pharmacother. 2004 Jan;38(1):9-14 [14742785.001]
  • [Cites] Arch Intern Med. 2004 Feb 9;164(3):305-12 [14769626.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):671-7 [14966090.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1522-30 [15042688.001]
  • [Cites] J Am Pharm Assoc (2003). 2004 May-Jun;44(3):337-49 [15191244.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2489-503 [15197212.001]
  • [Cites] J Altern Complement Med. 2004 Jun;10(3):560-4 [15253863.001]
  • [Cites] Pharmacotherapy. 2004 Jul;24(7):848-55 [15303449.001]
  • [Cites] J Altern Complement Med. 2004 Aug;10(4):660-6 [15353022.001]
  • [Cites] Drugs Aging. 2004;21(12):793-811 [15382959.001]
  • [Cites] Arch Intern Med. 2004 Oct 11;164(18):1957-9 [15477428.001]
  • [Cites] Arch Intern Med. 2004 Oct 11;164(18):2031-7 [15477439.001]
  • [Cites] Altern Ther Health Med. 2004 Sep-Oct;10(5):58-64 [15478787.001]
  • [Cites] J Am Geriatr Soc. 2004 Nov;52(11):1934-9 [15507075.001]
  • [Cites] J Am Geriatr Soc. 1988 Dec;36(12):1092-8 [3192887.001]
  • [Cites] DICP. 1990 Mar;24(3):321-3 [2316239.001]
  • [Cites] J Am Geriatr Soc. 1990 Oct;38(10):1082-7 [2229860.001]
  • [Cites] Chest. 1991 Apr;99(4):837-41 [2009784.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1825-32 [1888249.001]
  • [Cites] J Am Geriatr Soc. 1991 Nov;39(11):1093-9 [1753048.001]
  • [Cites] Med Care. 1992 Jul;30(7):646-58 [1614233.001]
  • [Cites] J Clin Epidemiol. 1992 Oct;45(10):1045-51 [1474400.001]
  • [Cites] J Am Geriatr Soc. 1994 Dec;42(12):1241-7 [7983285.001]
  • [Cites] Eur J Clin Pharmacol. 1999 Sep;55(7):533-6 [10501824.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):68-74 [15642877.001]
  • [Cites] Drugs Aging. 2005;22(1):69-82 [15663350.001]
  • [Cites] Ann Pharmacother. 2005 Mar;39(3):405-11 [15671088.001]
  • [Cites] Clin Ther. 2005 Jan;27(1):88-99 [15763610.001]
  • [Cites] Ann Pharmacother. 2005 Apr;39(4):643-8 [15741417.001]
  • [Cites] J Manag Care Pharm. 2005 Apr;11(3):211-9 [15804205.001]
  • [Cites] J Am Acad Nurse Pract. 2005 Apr;17(4):123-32 [15819637.001]
  • [Cites] Am J Geriatr Pharmacother. 2004 Dec;2(4):257-64 [15903284.001]
  • [Cites] Integr Cancer Ther. 2005 Jun;4(2):187-94 [15911931.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Sep;56(3):286-90 [15731916.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4719-25 [16034047.001]
  • [Cites] Br J Clin Pharmacol. 2005 Aug;60(2):137-44 [16042666.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Jul;61(5-6):453-9 [15912391.001]
  • [Cites] J Am Geriatr Soc. 2005 Aug;53(8):1282-9 [16078952.001]
  • [Cites] J Am Geriatr Soc. 2005 Sep;53(9):1518-23 [16137281.001]
  • [Cites] Drugs Aging. 2005;22(9):767-77 [16156680.001]
  • [Cites] Support Care Cancer. 2005 Oct;13(10):806-11 [15711946.001]
  • [Cites] J Gerontol Nurs. 2005 Sep;31(9):4-11 [16190007.001]
  • [Cites] Support Care Cancer. 2005 Nov;13(11):912-9 [15856334.001]
  • [Cites] Drugs Aging. 2005;22(10):877-85 [16245960.001]
  • [Cites] Am J Geriatr Pharmacother. 2005 Sep;3(3):168-79 [16257819.001]
  • [Cites] Oncol Nurs Forum. 2005 Nov;32(6):1115-22 [16270107.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Nov;61(10):769-73 [16200422.001]
  • [Cites] Urology. 2005 Dec;66(6):1223-8 [16360447.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Jun;Suppl Web Exclusives:W5-152-W5-166 [15840625.001]
  • [Cites] BMC Geriatr. 2006;6:1 [16403236.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 Feb;61(2):170-5 [16510861.001]
  • [Cites] Geriatr Nurs. 2006 Mar-Apr;27(2):118-29 [16638483.001]
  • [Cites] Am J Med Qual. 2006 May-Jun;21(3):162-8 [16679435.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 May;61(5):511-5 [16720750.001]
  • [Cites] J Manag Care Pharm. 2006 Jun;12(5):362-70 [16792442.001]
  • [Cites] Am J Geriatr Pharmacother. 2006 Jun;4(2):134-43 [16860260.001]
  • [Cites] J Pain Symptom Manage. 2006 Aug;32(2):148-54 [16877182.001]
  • [Cites] J Manag Care Pharm. 2006 Sep;12(7):537-45 [16981799.001]
  • [Cites] Head Neck. 2006 Oct;28(10):926-31 [16755583.001]
  • [Cites] Am J Clin Oncol. 2006 Oct;29(5):468-73 [17023781.001]
  • [Cites] J Soc Integr Oncol. 2006 Fall;4(4):157-69 [17022924.001]
  • [Cites] J Am Geriatr Soc. 2006 Oct;54(10):1516-23 [17038068.001]
  • [Cites] BMC Complement Altern Med. 2006;6:34 [17026768.001]
  • [Cites] J Am Geriatr Soc. 2007 Oct;55 Suppl 2:S247-52 [17910544.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2007 Oct;62(10):1172-81 [17921433.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Dec;5(4):345-51 [18179993.001]
  • [Cites] Drugs Aging. 2008;25(1):49-59 [18184029.001]
  • [Cites] Age Ageing. 2008 Jan;37(1):96-101 [17933759.001]
  • [Cites] Res Nurs Health. 2008 Feb;31(1):42-51 [18163447.001]
  • [Cites] Int J Clin Pharmacol Ther. 2008 Feb;46(2):72-83 [18218287.001]
  • [Cites] Med Care. 2008 Feb;46(2):167-73 [18219245.001]
  • [Cites] J Am Diet Assoc. 2008 Mar;108(3):483-94 [18313431.001]
  • [Cites] Drugs Aging. 2008;25(4):343-55 [18361544.001]
  • [Cites] J Gen Intern Med. 2008 Apr;23(4):399-404 [18373136.001]
  • [Cites] J Gerontol Nurs. 2008 Apr;34(4):8-17 [18429375.001]
  • [Cites] J Pain Symptom Manage. 2008 May;35(5):535-43 [18243638.001]
  • [Cites] Am J Emerg Med. 2008 Jul;26(6):697-700 [18606325.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):733-7 [18050360.001]
  • [Cites] Drugs Aging. 2008;25(8):683-92 [18665660.001]
  • [Cites] Drugs Aging. 2008;25(8):693-706 [18665661.001]
  • [Cites] Clin Interv Aging. 2008;3(2):383-9 [18686760.001]
  • [Cites] Ann Pharmacother. 2008 Jul;42(7):1017-25 [18594048.001]
  • [Cites] Am J Geriatr Pharmacother. 2008 Aug;6(3):147-52 [18775389.001]
  • [Cites] J Am Geriatr Soc. 2008 Jul;56(7):1306-11 [18482301.001]
  • [Cites] Oncology (Williston Park). 2008 Aug;22(9):1052-5, discussion 1055, 1058, 1060 [18777955.001]
  • [Cites] Drugs Aging. 2008;25(11):933-46 [18947261.001]
  • [Cites] Curr Treat Options Oncol. 2008 Jun;9(2-3):191-203 [18663583.001]
  • [Cites] Age Ageing. 2008 Nov;37(6):673-9 [18829684.001]
  • [Cites] JAMA. 2008 Dec 24;300(24):2867-78 [19109115.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Jan;18(1):53-61 [19111015.001]
  • [Cites] Arch Gerontol Geriatr. 2009 Mar-Apr;48(2):186-90 [18313773.001]
  • [Cites] Eur J Clin Pharmacol. 2009 Feb;65(2):199-207 [18807252.001]
  • [Cites] Drugs Aging. 2009;26(2):123-33 [19220069.001]
  • [Cites] Am J Geriatr Pharmacother. 2009 Feb;7(1):20-5 [19281937.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2009 May;64(5):599-609 [19264957.001]
  • [Cites] Ann Pharmacother. 2009 Feb;43(2):177-84 [19193583.001]
  • [Cites] Am J Geriatr Pharmacother. 2009 Apr;7(2):84-92 [19447361.001]
  • [Cites] J Am Geriatr Soc. 2009 Jun;57(6):1007-14 [19467144.001]
  • [Cites] Am J Geriatr Pharmacother. 2009 Jun;7(3):151-8 [19616183.001]
  • [Cites] Arch Intern Med. 2009 Jul 27;169(14):1326-32 [19636035.001]
  • [Cites] BMC Geriatr. 2009;9:30 [19627577.001]
  • [Cites] Age Ageing. 2009 Sep;38(5):603-6 [19435757.001]
  • [Cites] Am J Geriatr Pharmacother. 2006 Dec;4(4):297-305 [17296535.001]
  • (PMID = 20418534.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / 1 K08 AG24842; United States / NIA NIH HHS / AG / K23 AG026749-01; United States / NIA NIH HHS / AG / T32 AG19134
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 192
  • [Other-IDs] NLM/ PMC3227983
  •  go-up   go-down


7. ||||||.... 59%  Cooper IF, Siadaty MS: 'Steroids' associated with 'Polypharmacy Therapy': Top Publications. BioMedLib Review; Steroid;PolypharmacyTherapy:705664151. ISSN: 2331-5717. 2014/4/25
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Steroids' associated with 'Polypharmacy Therapy': Top Publications.
  • Background: There are articles published each month which present 'steroid' for 'polypharmacy therapy'.
  • Finding such articles is important for researchers, clinicians, and patients.
  • In group one there are publications with the strongest evidence of association. We focused finding the most relevant publications pertinent to our goal, rather than combining them into a conclusion section. Such textual synthesis will be the focus of our next project.
  • Gleason LJ et al: Polypharmacy in the HIV-infected older adult population.
  • Reason B et al: The impact of polypharmacy on the health of Canadian seniors.
  • Lee HW et al: The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release.
  • Jenny JL et al: Nurses opinion on the attributes of polypharmacy in patient safety.
  • Carvalho MF et al: Polypharmacy among the elderly in the city of São Paulo, Brazil - SABE Study.
  • Sehgal V et al: Polypharmacy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospital.
  • Steinsvoll PS: [Polypharmacy in the elderly].
  • Heppner HJ et al: Polypharmacy in the elderly from the clinical toxicologist perspective.
  • Mazzocato C et al: [Polypharmacy and the elderly: neither too much nor too little].
  • Mansur N et al: Looking beyond polypharmacy: quantification of medication regimen complexity in the elderly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 705664151.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


8. |||||||||. 102%  Zadak Z, Hyspler R, Ticha A, Vlcek J: Polypharmacy and malnutrition. Curr Opin Clin Nutr Metab Care; 2013 Jan;16(1):50-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy and malnutrition.
  • PURPOSE OF REVIEW: Malnutrition and polypharmacy increase with age and polymorbidity and their relationship is based on a number of mechanisms.
  • The occurrence of malnutrition in both in-patients and out-patients and its dependence on polymorbidity and age are well known, but the interrelation of polypharmacy and malnutrition has been far less investigated.
  • The countries with the highest occurrence of polypharmacy in Europe include the Czech Republic and Finland, whereas the lowest prevalence of polypharmacy is found in Norway and the Netherlands.
  • RECENT FINDINGS: The occurrence, consequences and mutual relationship of malnutrition and polypharmacy are described.
  • SUMMARY: The effect of polypharmacy on nutrition is suggested from the observations that problems with nutrition occur mostly in elderly patients, and that such patients are more frequently subject to polypharmacy.
  • [MeSH-major] Elder Nutritional Physiological Phenomena. Malnutrition / epidemiology. Polypharmacy

  • MedlinePlus Health Information. consumer health - Malnutrition.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23201650.001).
  • [ISSN] 1473-6519
  • [Journal-full-title] Current opinion in clinical nutrition and metabolic care
  • [ISO-abbreviation] Curr Opin Clin Nutr Metab Care
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


9. |||||||||. 98%  Gokula M, Holmes HM: Tools to reduce polypharmacy. Clin Geriatr Med; 2012 May;28(2):323-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tools to reduce polypharmacy.
  • The reduction in polypharmacy and avoidance of inappropriate medications is a common goal in the care of older persons, regardless of setting.
  • Ultimately, optimizing prescribing by reducing polypharmacy and avoiding inappropriate medications is a highly individualized process for each patient, and clinicians will have to use extensive clinical judgment in using the tools presented here.
  • [MeSH-major] Drug Prescriptions / standards. Inappropriate Prescribing / prevention & control. Polypharmacy. Practice Guidelines as Topic

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22500546.001).
  • [ISSN] 1879-8853
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / K23 AG038476; United States / NIA NIH HHS / AG / K23AG038476
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  •  go-up   go-down


10. |||||||||. 98%  Talasz H, Lechleitner M: Polypharmacy and incontinence. Z Gerontol Geriatr; 2012 Aug;45(6):464-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy and incontinence.
  • Polypharmacy as well as urinary incontinence are common geriatric problems.
  • [MeSH-major] Drug Interactions. Drug-Related Side Effects and Adverse Reactions / epidemiology. Polypharmacy. Urinary Incontinence / epidemiology


11. |||||||||. 97%  Yamanouchi Y: [How everyone recognize about polypharmacy?]. Seishin Shinkeigaku Zasshi; 2012;114(6):683-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [How everyone recognize about polypharmacy?].
  • The report of this conference said "In order to accelerate improvement to single dosage and loss in quantity, we should be grasped of the actual condition about the polypharmacy and extensive medication of antipsychotics for schizophrenic patients, and we should be discussed about the methods of information and evaluation".
  • But there is no evidence about the polypharmacy is good or bad, and no one knows actual condition about the Japanese antipsychotics medications.
  • In order to answer this question, we are undergoing "the clinical study about safety and effective correction of polypharmacy and agent extensive medication of antipsychotics".
  • [MeSH-major] Antipsychotic Agents / administration & dosage. Drug Prescriptions / statistics & numerical data. Polypharmacy
  • [MeSH-minor] Drug Therapy, Combination. Humans. Japan. Recognition (Psychology)

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22844819.001).
  • [ISSN] 0033-2658
  • [Journal-full-title] Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica
  • [ISO-abbreviation] Seishin Shinkeigaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


12. |||||||||. 96%  Zink M, Englisch S, Meyer-Lindenberg A: Polypharmacy in schizophrenia. Curr Opin Psychiatry; 2010 Mar;23(2):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in schizophrenia.
  • RECENT FINDINGS: Polypharmacy intends to address different aspects of treatment resistance, most importantly insufficient response of psychotic positive and negative symptoms, but also cognitive disturbances, affective comorbidity, obsessive-compulsive syndromes and side-effects of antipsychotic drugs.
  • SUMMARY: In general, rigorous data on combination therapy in schizophrenia are rare and further randomized controlled trials, naturalistic trials and head-to-head-trials are necessary.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Polypharmacy. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20051861.001).
  • [ISSN] 1473-6578
  • [Journal-full-title] Current opinion in psychiatry
  • [ISO-abbreviation] Curr Opin Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Number-of-references] 126
  •  go-up   go-down


13. |||||||||. 94%  Zink M, Englisch S, Meyer-Lindenberg A: [Polypharmacy in schizophrenia]. Nervenarzt; 2011 Jul;82(7):853-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy in schizophrenia].
  • [Transliterated title] Polypharmazie bei schizophrenen Psychosen.
  • RESULTS: Polypharmacy aims to address several aspects of treatment resistance and side effects of antipsychotics.
  • CONCLUSIONS: In general, rigorous data on combination therapy in schizophrenia are rare, and further randomized controlled trials (RCT), naturalistic and head-to-head-studies are necessary.
  • [MeSH-major] Antidepressive Agents / administration & dosage. Antimanic Agents / administration & dosage. Antipsychotic Agents / administration & dosage. Polypharmacy. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21165589.001).
  • [ISSN] 1433-0407
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antimanic Agents; 0 / Antipsychotic Agents
  •  go-up   go-down


14. |||||||||. 92%  von Lueder TG, Atar D: Comorbidities and polypharmacy. Heart Fail Clin; 2014 Apr;10(2):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidities and polypharmacy.
  • Polypharmacy in HF is common, has increased throughout the past 2 decades, and may pose a risk for adverse drug interactions, accidental overdosing, or medication nonadherence.
  • Polypharmacy, in particular in the elderly, is rarely assessed in traditional clinical trials, highlighting a need for entirely novel HF research strategies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2014 Elsevier Inc. All rights reserved.
  • (PMID = 24656112.001).
  • [ISSN] 1551-7136
  • [Journal-full-title] Heart failure clinics
  • [ISO-abbreviation] Heart Fail Clin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Comorbidities / Elderly / Heart failure / Polypharmacy
  •  go-up   go-down


15. ||||||||.. 85%  Kaufman G: Polypharmacy in older adults. Nurs Stand; 2011 May 25-31;25(38):49-55; quiz 58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in older adults.
  • This article explores the issue of polypharmacy in older adults.
  • The risks of adverse drug reactions and adverse drug interactions linked to polypharmacy are explored.
  • [MeSH-major] Polypharmacy

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21706978.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. ||||||||.. 81%  Gosch M, Jeske M, Kammerlander C, Roth T: Osteoporosis and polypharmacy. Z Gerontol Geriatr; 2012 Aug;45(6):450-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoporosis and polypharmacy.
  • Due to drug interactions and patient compliance, polypharmacy is often mentioned as a reason for undertreatment.
  • However, patients with a polypharmacy are at a higher risk of fractures and should receive osteoporosis treatment, if indicated.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Drug Interactions. Drug-Related Side Effects and Adverse Reactions / epidemiology. Osteoporosis / epidemiology. Osteoporotic Fractures / epidemiology. Polypharmacy

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22806642.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents
  •  go-up   go-down


17. ||||||||.. 80%  Strehblow C, Smeikal M, Fasching P: Polypharmacy and excessive polypharmacy in octogenarians and older acutely hospitalized patients. Wien Klin Wochenschr; 2014 Apr;126(7-8):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy and excessive polypharmacy in octogenarians and older acutely hospitalized patients.
  • AIM: The aim of this study was to assess the occurrence of polypharmacy and excessive polypharmacy in very old hospitalized patients based on their comorbidities.
  • RESULTS: Chronic pulmonary disease [odds ratio (OR): 2.40], diabetes mellitus with (OR: 4.65) or without (OR: 1.65) microvascular complications, congestive heart failure (OR: 2.37), connective tissue disease (OR: 3.02), and peripheral vascular disease (OR: 2.30) were statistically significantly associated with polypharmacy, while some of these diseases were also associated with excessive polypharmacy.
  • "Admission for myocardial infarction" was associated with an increase in pharmaceuticals during hospital stay, whereas a known diagnosis of dementia or metastatic malignant disease was protective against a further increase in medications.
  • CONCLUSIONS: Several medical conditions seem to predispose to polypharmacy in very old patients.
  • Physicians should pay attention to the identified predictors in very old patients, as polypharmacy may lead to adverse events and unnecessary hospitalization.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24445522.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


18. |||||||... 75%  Chiang-Hanisko L, Tan JY, Chiang LC: [Polypharmacy issues in older adults]. Hu Li Za Zhi; 2014 Jun;61(3):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy issues in older adults].
  • Polypharmacy is a major concern in the care of older adults.
  • Polypharmacy is a term that refers to a high number of prescribed medications, usually five and above, or the use of more medications than is clinically justified.
  • Although medications are an important factor in improving and maintaining the quality of life of older adults, polypharmacy increases the risks of morbidity and mortality, loss of functional independence, and a multiplicity of cognitive and physical problems in this population.
  • This article examines issues related to polypharmacy in older adults and identifies nursing strategies and interventions to detect and prevent polypharmacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24899563.001).
  • [ISSN] 0047-262X
  • [Journal-full-title] Hu li za zhi The journal of nursing
  • [ISO-abbreviation] Hu Li Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Keywords] NOTNLM ; older adults / polypharmacy
  •  go-up   go-down


19. |||||||... 73%  Jesson B: Minimising the risk of polypharmacy. Nurs Older People; 2011 May;23(4):14-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimising the risk of polypharmacy.
  • Polypharmacy holds particular risks for the older population, which nurses are in a good position to recognise and minimise.
  • The aim of this article is to highlight the reasons why polypharmacy presents such a risk to older people and to consider what actions can be taken to address this problem.
  • [MeSH-major] Polypharmacy. Risk Reduction Behavior

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21675164.001).
  • [ISSN] 1472-0795
  • [Journal-full-title] Nursing older people
  • [ISO-abbreviation] Nurs Older People
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. |||||||... 72%  Flahaut J: [The theriac Diatessaron; oligopharmacy against polypharmacy]. Rev Hist Pharm (Paris); 2010 Oct;58(367):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The theriac Diatessaron; oligopharmacy against polypharmacy].
  • [Transliterated title] La thériaque Diatessaron Oligopharmacie contre polypharmacie.
  • The theriac of Andromachus was the symbol of polypharmacy and the theriac Diatessaron was a product of oligopharmacy.
  • [MeSH-major] Antidotes / history. Materia Medica / history. Pharmacy / history
  • [MeSH-minor] History, 18th Century. Phytotherapy / history. Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21560364.001).
  • [ISSN] 0035-2349
  • [Journal-full-title] Revue d'histoire de la pharmacie
  • [ISO-abbreviation] Rev Hist Pharm (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antidotes; 0 / Materia Medica
  •  go-up   go-down


21. |||||||... 71%  Sommeregger U, Iglseder B, Böhmdorfer B, Benvenuti-Falger U, Dovjak P, Lechleitner M, Otto R, Roller RE, Gosch M: [Polypharmacy and falls in the Elderly]. Wien Med Wochenschr; 2010 Jun;160(11-12):293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy and falls in the Elderly].
  • [Transliterated title] Polypharmazie und Stürze im Alter.
  • Main causes are the combination of age-related physiological changes with multimorbidity and subsequent polypharmacy.
  • [MeSH-minor] Aged. Aged, 80 and over. Comorbidity. Drug Interactions. Drug Therapy, Combination / adverse effects. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Falls.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20640927.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Prescription Drugs
  •  go-up   go-down


22. |||||||... 71%  Hovstadius B, Petersson G: Factors leading to excessive polypharmacy. Clin Geriatr Med; 2012 May;28(2):159-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors leading to excessive polypharmacy.
  • There are numerous risk factors for patients to develop excessive polypharmacy.
  • Risk factors associated with patient behavior, such as patient’s self medication with all types of medications, have not been observed to the same extent but might be at the same level of importance for patients developing excessive polypharmacy.
  • The few studies conducted regarding the large variation in physicians’ individual prescribing practices, in terms of polypharmacy, add another perspective to the complexity of the area.
  • Interventions aiming to improve communication between GP and hospital specialist, to create support systems for medical reviews that include all patients’ medications, and to improve the knowledge of multiple prescribing might have the largest potential to better manage excessive polypharmacy.
  • [MeSH-major] Pharmaceutical Preparations / administration & dosage. Physician's Practice Patterns. Polypharmacy. Self Medication

  • MedlinePlus Health Information. consumer health - Medicines.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22500536.001).
  • [ISSN] 1879-8853
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


23. |||||||... 70%  Barnes TR, Paton C: Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs; 2011 May;25(5):383-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic polypharmacy in schizophrenia: benefits and risks.
  • Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient.
  • The relatively widespread use of antipsychotic polypharmacy identified in cross-sectional surveys reflects not only the addition of a second antipsychotic to boost therapeutic response, but also the use of as-required antipsychotic medication (mainly to treat disturbed behaviour), gradual cross-titration while switching from one antipsychotic to another, and augmentation of clozapine with a second antipsychotic where the illness has failed to respond adequately to an optimized trial of clozapine.
  • Also reviewed are examples of systematic, practice-based interventions designed to reduce the prevalence of antipsychotic polypharmacy, most of which have met with only modest success.
  • [MeSH-major] Antipsychotic Agents / adverse effects. Antipsychotic Agents / therapeutic use. Psychotic Disorders / drug therapy. Schizophrenia / drug therapy
  • [MeSH-minor] Drug Therapy, Combination. Female. Guidelines as Topic. Humans. Male. Physician's Practice Patterns. Polypharmacy


24. |||||||... 69%  Planton J, Edlund BJ: Strategies for reducing polypharmacy in older adults. J Gerontol Nurs; 2010 Jan;36(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for reducing polypharmacy in older adults.
  • Polypharmacy is a major concern in the care of older adults.
  • [MeSH-major] Geriatric Nursing / organization & administration. Polypharmacy. Safety Management / organization & administration

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • (PMID = 20047247.001).
  • [ISSN] 0098-9134
  • [Journal-full-title] Journal of gerontological nursing
  • [ISO-abbreviation] J Gerontol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. |||||||... 67%  Ingham G: Polypharmacy. Nurs Stand; 2012 Apr 25-May 1;26(34):59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy.
  • [MeSH-major] Drug Therapy. Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22787875.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. ||||||.... 64%  Chen H, Patel A, Sherer J, Aparasu R: The definition and prevalence of pediatric psychotropic polypharmacy. Psychiatr Serv; 2011 Dec;62(12):1450-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The definition and prevalence of pediatric psychotropic polypharmacy.
  • OBJECTIVES: Using increasingly stringent criteria, this study evaluated the prevalence of psychotropic polypharmacy among children on the basis of duration of overlap between two or more psychotropic medications.
  • METHODS: The prevalence of psychotropic polypharmacy was defined as receiving ≥ 14 days, ≥ 30 days, ≥ 60 days, and ≥ 90 days of overlapping psychotropic prescription fills.
  • A sensitivity analysis was also conducted to explore the extent to which the cross-sectional operational definitions of polypharmacy used in the published literature identified patients who were prescribed psychotropic combinations on a long-term basis.
  • The observed rate of polypharmacy dropped to 27.2% with 30 days of overlap and to 20.9% with 60 days of overlap.
  • Using a 60-day overlap in psychotropic drugs as a cutoff between short-term and long-term polypharmacy, analyses showed that 14%-46% of patients identified by cross-sectional definitions as receiving polypharmacy had likely received combination treatment on a temporary rather than on a long-term basis.
  • In addition, cross-sectional definitions failed to identify 18%-44% of patients classified as receiving long-term polypharmacy (≥ 60-day overlap).
  • CONCLUSIONS: The observed rate of polypharmacy dropped with increasingly stringent operational definitions for polypharmacy.
  • The findings suggest that considerable differences arise when comparing rates of polypharmacy across studies with inconsistent operational definitions.
  • [MeSH-major] Drug Therapy, Combination / utilization. Mental Disorders / drug therapy. Polypharmacy. Psychotropic Drugs / therapeutic use

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22193792.001).
  • [ISSN] 1557-9700
  • [Journal-full-title] Psychiatric services (Washington, D.C.)
  • [ISO-abbreviation] Psychiatr Serv
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Psychotropic Drugs
  •  go-up   go-down


27. ||||||.... 64%  Taylor D: Polypharmacy. Nurs Stand; 2011 Oct 26-Nov 1;26(8):59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy.
  • [MeSH-major] Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22165808.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. ||||||.... 64%  Holmes HM: Polypharmacy. Clin Geriatr Med; 2012 May;28(2):xiii-xiv
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy.
  • [MeSH-major] Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22500547.001).
  • [ISSN] 1879-8853
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / K23 AG038476
  • [Publication-type] Editorial
  • [Publication-country] United States
  •  go-up   go-down


29. ||||||.... 64%  Suchopár J, Prokes M: [Polypharmacy and drug interactions]. Vnitr Lek; 2011 Sep;57(9):755-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy and drug interactions].
  • [Transliterated title] Polypragmazie a lékové interakce.
  • The growing consumption of drugs and other numerous factors relates to the increasing incidence of polypharmacy.
  • Some works show that it is possible to satisfactorily address the issues of polypharmacy, but it requires great courage and an interdisciplinary approach involving modern information technology.
  • [MeSH-major] Drug Interactions. Polypharmacy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21957770.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


30. ||||||.... 62%  Heppner HJ, Christ M, Gosch M, Mühlberg W, Bahrmann P, Bertsch T, Sieber C, Singler K: Polypharmacy in the elderly from the clinical toxicologist perspective. Z Gerontol Geriatr; 2012 Aug;45(6):473-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in the elderly from the clinical toxicologist perspective.
  • INTRODUCTION: Polypharmacy is closely associated with multimorbidity in the elderly and can lead to problems and drug interactions.
  • AIM: This study assessed polypharmacy in the elderly, tracking inquiries to the Poison Information Centre Nuremberg (PICN) and patients needing toxicological intensive care therapy.
  • [MeSH-major] Drug Interactions. Drug-Related Side Effects and Adverse Reactions / mortality. Poisoning / mortality. Polypharmacy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Poisoning.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22915001.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. ||||||.... 61%  Volpe M, Chin D, Paneni F: The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol; 2010 Feb;24(1):9-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenge of polypharmacy in cardiovascular medicine.
  • However, the chronic use of five or more medications, defined as polypharmacy, has shown to be neither always efficacious nor safe.
  • Polypharmacy is associated with an increased morbidity and costs.
  • This review will focus on challenges of polypharmacy in CV medicine, illustrating potential options to face this emerging crisis.
  • [MeSH-major] Cardiovascular Agents / therapeutic use. Cardiovascular Diseases / drug therapy. Polypharmacy

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817871.001).
  • [ISSN] 1472-8206
  • [Journal-full-title] Fundamental & clinical pharmacology
  • [ISO-abbreviation] Fundam Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cardiovascular Agents
  • [Number-of-references] 83
  •  go-up   go-down


32. ||||||.... 61%  Thürmann PA: [Polypharmacy]. MMW Fortschr Med; 2014 May 28;156(10):56-61; quiz 62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy].
  • [Transliterated title] Polypharmazie. Treiben Sie den Teufel nicht mit dem Beelzebub aus!
  • [MeSH-major] Drug Therapy, Combination / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24930234.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


33. ||||||.... 59%  Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong KH, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N: Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Pharmacopsychiatry; 2012 Jan;45(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).
  • OBJECTIVE: This study aimed to identify trends in the use of antipsychotic polypharmacy (APP) and their demographic and clinical correlates in the treatment of schizophrenia in Asia between 2001 and 2009.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Physician's Practice Patterns. Polypharmacy. Schizophrenia / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Asia. Cohort Studies. Delayed-Action Preparations / therapeutic use. Drug Prescriptions. Drug Therapy, Combination. Female. Health Surveys. Humans. Logistic Models. Longitudinal Studies. Male. Middle Aged. Practice Guidelines as Topic. Psychiatry. Schizophrenic Psychology. Young Adult

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21989602.001).
  • [ISSN] 1439-0795
  • [Journal-full-title] Pharmacopsychiatry
  • [ISO-abbreviation] Pharmacopsychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Delayed-Action Preparations
  •  go-up   go-down


34. ||||||.... 59%  Foucher N, Lahille B, Bernard N, Poutrel S, Pedebosq S, Bonnet F, Morlat P, Pometan JP: [Influence of hospitalisation on the elderly people polypharmacy]. Rev Med Interne; 2009 Jan;30(1):20-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of hospitalisation on the elderly people polypharmacy].
  • INTRODUCTION: The objective of this study was to analyse the influence of hospitalisation on the polypharmacy of elderly people in internal medicine.
  • CONCLUSION: These results pointed out firstly the polypharmacy observed in elderly patients and secondly the difficulty to reassess prescriptions.
  • Our results should heighten clinicians' awareness of polypharmacy of elderly patients and of the usefulness of performing an individual assessment of the various drugs prescribed to a patient.
  • [MeSH-major] Drug Prescriptions / statistics & numerical data. Hospitalization. Polypharmacy

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619717.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


35. ||||||.... 59%  Suokas JT, Suvisaari JM, Haukka J, Korhonen P, Tiihonen J: Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol; 2013 Apr;48(4):631-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Description of long-term polypharmacy among schizophrenia outpatients.
  • OBJECTIVE: This large nationwide study describes the prevalence and predictors of long-term antipsychotic polypharmacy among patients with schizophrenia.
  • Entry to the cohort was defined from the first hospitalization for schizophrenia during the years 2000-2007, and the date of assessment of antipsychotic polypharmacy was March 1, 2007.
  • Antipsychotic polypharmacy was defined as overlapping of two or more filled prescriptions of antipsychotics for over 60 days.
  • RESULTS: In a total 16,083 patients with schizophrenia the prevalence of antipsychotic polypharmacy was 46.2 % (N = 7,436, mean age 47.5 years, male 55 %).
  • The longer the duration of schizophrenia, the more common the antipsychotic polypharmacy.
  • Long index hospitalization and being male significantly associated with antipsychotic polypharmacy among all schizophrenia patients.
  • Especially, in chronic schizophrenia patients, the previous use of benzodiazepine like agents was associated with antipsychotic polypharmacy, but the use of antidepressants associated with less frequent antipsychotic polypharmacy.
  • CONCLUSIONS: Antipsychotic polypharmacy was widely prevalent among patients with schizophrenia and it was associated with long hospitalizations and long duration of illness.
  • Benzodiazepine use was associated with increased risk and antidepressant use with decreased risk of antipsychotic polypharmacy when the effect of other clinical and socioeconomic factors was adjusted.
  • Research is needed of risks and benefits of antipsychotic polypharmacy and augmentation of antipsychotic with other psychoactive drugs.

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23007295.001).
  • [ISSN] 1433-9285
  • [Journal-full-title] Social psychiatry and psychiatric epidemiology
  • [ISO-abbreviation] Soc Psychiatry Psychiatr Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


36. ||||||.... 57%  Hazra M, Uchida H, Sproule B, Remington G, Suzuki T, Mamo DC: Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry Clin Neurosci; 2011 Dec;65(7):676-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia.
  • The objective was to examine effects of active interventions on physician's prescribing of antipsychotic polypharmacy.
  • During the intervening period, a pharmacist monitored prescriptions with antipsychotic polypharmacy and contacted corresponding prescribers to provide education on risks of polypharmacy.
  • Moreover, educational sessions on polypharmacy were presented to inpatient and outpatient teams.
  • A three-fold decrease in the prevalence of antipsychotic polypharmacy was observed between 2006 (18.3%) and 2008 (6.6%).
  • Thus, active monitoring of prescriptions with educational interventions could reduce antipsychotic polypharmacy.
  • [MeSH-major] Antipsychotic Agents. Inappropriate Prescribing / prevention & control. Pharmacists. Physician's Practice Patterns / statistics & numerical data. Polypharmacy. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2011 The Authors. Psychiatry and Clinical Neurosciences © 2011 Japanese Society of Psychiatry and Neurology.
  • (PMID = 22176287.001).
  • [ISSN] 1440-1819
  • [Journal-full-title] Psychiatry and clinical neurosciences
  • [ISO-abbreviation] Psychiatry Clin. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


37. ||||||.... 57%  Díaz-Caneja CM, Espliego A, Parellada M, Arango C, Moreno C: Polypharmacy with antidepressants in children and adolescents. Int J Neuropsychopharmacol; 2014 Jul;17(7):1063-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy with antidepressants in children and adolescents.
  • A Medline search from inception until February 2012 was performed to identify epidemiological and clinical studies, reviews and reports containing potentially relevant information on polypharmacy with antidepressants in young people.
  • There has been an increase in polypharmacy in children and adolescents involving antidepressants in recent years.
  • Most information regarding efficacy and safety of polypharmacy patterns was provided by case series and open-label studies.
  • The use of polypharmacy with antidepressants has become a regular practice in clinical settings.
  • Although there is still little efficacy and safety information, preliminary evidence points to the potential clinical usefulness of some polypharmacy patterns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23190624.001).
  • [ISSN] 1469-5111
  • [Journal-full-title] The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)
  • [ISO-abbreviation] Int. J. Neuropsychopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


38. ||||||.... 55%  Ravona-Springer R, Davidson M: Considerations in psychotropic treatments in dementia--can polypharmacy be avoided? Int J Neuropsychopharmacol; 2014 Jul;17(7):1107-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Considerations in psychotropic treatments in dementia--can polypharmacy be avoided?
  • In the present review, we discuss these factors in the context of polypharmacy and suggest further clinical and research strategies that may enable more accurate and less harmful therapeutic strategies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23842111.001).
  • [ISSN] 1469-5111
  • [Journal-full-title] The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)
  • [ISO-abbreviation] Int. J. Neuropsychopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. |||||..... 55%  Shah BM, Hajjar ER: Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med; 2012 May;28(2):173-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy, adverse drug reactions, and geriatric syndromes.
  • The elderly are at risk for polypharmacy, which is associated with significant consequences such as adverse effects, medication nonadherence, drug-drug and drug-disease interactions, and increased risk of geriatric syndromes.
  • Providers should evaluate all existing medications at each patient visit for appropriateness and weigh the risks and benefits of starting new medications to minimize polypharmacy.
  • [MeSH-major] Drug Interactions. Drug-Related Side Effects and Adverse Reactions. Polypharmacy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22500537.001).
  • [ISSN] 1879-8853
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. |||||..... 54%  Neuner-Jehle S: [Less is more - how to prevent polypharmacy?]. Praxis (Bern 1994); 2013 Jan 2;102(1):21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Less is more - how to prevent polypharmacy?].
  • [Transliterated title] Weniger ist mehr - wie Polypharmazie vermeiden?
  • There is time for action, as polypharmacy patients have an elevated risk of morbidity, hospitalization, nursing home placement and death.
  • Reducing polypharmacy is a challenge, (yet) out of daily routine and has to be performed together with the patient (shared decision making).
  • The potential benefit for patients by reducing polypharmacy is enormous: Less is more!
  • [MeSH-major] Drug Therapy, Combination / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23384927.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


41. |||||..... 53%  Jyrkkä J, Mursu J, Enlund H, Lönnroos E: Polypharmacy and nutritional status in elderly people. Curr Opin Clin Nutr Metab Care; 2012 Jan;15(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy and nutritional status in elderly people.
  • PURPOSE OF REVIEW: Increasing use of drugs among elderly people has raised concerns about possible negative health outcomes, including malnutrition, associated with polypharmacy.
  • Evidence about the association of polypharmacy with nutritional status is scarce.
  • This review summarizes the relevant evidence regarding polypharmacy and nutritional status in elderly people.
  • Studies indicate also an association between polypharmacy and weight changes.
  • SUMMARY: On the basis of available evidence, the role of polypharmacy on nutritional status among elderly people is unclear.
  • Longitudinal studies with careful adjustment for underlying diseases are needed to explore association between polypharmacy and malnutrition.
  • [MeSH-major] Drug-Related Side Effects and Adverse Reactions. Malnutrition / etiology. Nutritional Status. Polypharmacy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Malnutrition.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22108093.001).
  • [ISSN] 1473-6519
  • [Journal-full-title] Current opinion in clinical nutrition and metabolic care
  • [ISO-abbreviation] Curr Opin Clin Nutr Metab Care
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


42. |||||..... 53%  Vyas A, Pan X, Sambamoorthi U: Chronic Condition Clusters and Polypharmacy among Adults. Int J Family Med; 2012;2012:193168
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic Condition Clusters and Polypharmacy among Adults.
  • Objective. The primary objective of the study was to estimate the rates of polypharmacy among individuals with multimorbidity defined as chronic condition clusters and examine their associations with polypharmacy.
  • Chi-square tests and logistic regressions were performed to analyze the association between polypharmacy and multimorbidity.
  • Results. Polypharmacy rates varied from a low of 7.2% among those with respiratory cluster to a high of 64.1% among those with all three disease clusters.
  • Individual with cardiometabolic conditions alone or in combination with other disease clusters were more likely to have polypharmacy.
  • Compared to those with musculoskeletal and respiratory conditions, those with cardiometabolic and respiratory conditions had 1.68 times higher likelihood of polypharmacy.
  • Conclusions. Rates of polypharmacy differed by specific disease clusters.
  • Individuals with cardiometabolic condition were particularly at high risk of polypharmacy, suggesting greater surveillance for adverse drug interaction in this group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Fam Med. 2012 Mar-Apr;10(2):142-51 [22412006.001]
  • [Cites] Eur J Intern Med. 2011 Dec;22(6):597-602 [22075287.001]
  • [Cites] Ann Fam Med. 2003 May-Jun;1(1):8-14 [15043174.001]
  • [Cites] Milbank Q. 1989;67(3-4):450-84 [2534562.001]
  • [Cites] J Am Geriatr Soc. 1988 Feb;36(2):142-9 [3276767.001]
  • [Cites] J Clin Epidemiol. 1998 May;51(5):367-75 [9619963.001]
  • [Cites] Arch Intern Med. 2000 Jul 24;160(14):2129-34 [10904455.001]
  • [Cites] J Clin Epidemiol. 2001 Jul;54(7):661-74 [11438406.001]
  • [Cites] Ann Pharmacother. 2001 Sep;35(9):1004-9 [11573845.001]
  • [Cites] Health Qual Life Outcomes. 2004;2:51 [15380021.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Jun;Suppl Web Exclusives:W5-152-W5-166 [15840625.001]
  • [Cites] Ann Fam Med. 2005 May-Jun;3(3):223-8 [15928225.001]
  • [Cites] Arch Intern Med. 2005 Sep 12;165(16):1842-7 [16157827.001]
  • [Cites] Qual Life Res. 2006 Feb;15(1):83-91 [16411033.001]
  • [Cites] BMJ. 2007 May 19;334(7602):1016-7 [17510108.001]
  • [Cites] Health Qual Life Outcomes. 2007;5:52 [17683600.001]
  • [Cites] J Gen Intern Med. 2007 Dec;22 Suppl 3:403-7 [18026809.001]
  • [Cites] J Gen Intern Med. 2007 Dec;22 Suppl 3:408-18 [18026810.001]
  • [Cites] Clin Interv Aging. 2008;3(2):383-9 [18686760.001]
  • [Cites] J Intern Med. 2009 Feb;265(2):288-95 [19192038.001]
  • [Cites] Health Aff (Millwood). 2009 Mar-Apr;28(2):w358-67 [19240056.001]
  • [Cites] Med Care. 2009 Jun;47(6):618-25 [19433993.001]
  • [Cites] BMC Public Health. 2010;10:718 [21092218.001]
  • [Cites] PLoS One. 2012;7(2):e32190 [22393389.001]
  • [Cites] J Clin Epidemiol. 2002 Aug;55(8):809-17 [12384196.001]
  • [Cites] J Am Acad Nurse Pract. 2005 Apr;17(4):123-32 [15819637.001]
  • [Cites] Res Social Adm Pharm. 2005 Sep;1(3):446-59 [17138489.001]
  • [Cites] Arch Gerontol Geriatr. 2008 Jan-Feb;46(1):41-55 [17403548.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Jul;64(7):715-22 [18385990.001]
  • [Cites] J Am Geriatr Soc. 2009 Mar;57(3):560-1 [19278399.001]
  • [Cites] Arzneimittelforschung. 2010;60(2):57-63 [20329652.001]
  • [Cites] Ir Med J. 2010 Sep;103(8):236-8 [21046863.001]
  • [Cites] Med Care Res Rev. 2011 Aug;68(4):387-420 [21813576.001]
  • [Cites] Int J Chron Obstruct Pulmon Dis. 2011;6:493-501 [22069360.001]
  • [Cites] AORN J. 1999 Mar;69(3):619-22, 625, 627-8 [11957456.001]
  • (PMID = 22900173.001).
  • [ISSN] 2090-2050
  • [Journal-full-title] International journal of family medicine
  • [ISO-abbreviation] Int J Family Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC3415173
  •  go-up   go-down


43. |||||..... 53%  Mazzocato C, David S, Benaroyo L, Monod S: [Polypharmacy and the elderly: neither too much nor too little]. Rev Med Suisse; 2013 May 15;9(386):1026, 1028-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polypharmacy and the elderly: neither too much nor too little].
  • Elderly persons are at high risk of polypharmacy.
  • Polypharmacy has been associated with numerous adverse outcomes, such as poorer quality of life, higher morbidity and mortality.
  • [MeSH-major] Drug Prescriptions / standards. Polypharmacy

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23745236.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


44. |||||..... 53%  Wallace JL: Polypharmacy of osteoarthritis: the perfect intestinal storm. Dig Dis Sci; 2013 Nov;58(11):3088-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy of osteoarthritis: the perfect intestinal storm.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Gastrointestinal Diseases / chemically induced. Osteoarthritis / drug therapy. Polypharmacy

  • MedlinePlus Health Information. consumer health - Osteoarthritis.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23884755.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


45. |||||..... 53%  Mizokami F, Koide Y, Noro T, Furuta K: Polypharmacy with common diseases in hospitalized elderly patients. Am J Geriatr Pharmacother; 2012 Apr;10(2):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy with common diseases in hospitalized elderly patients.
  • BACKGROUND: Elderly persons are exposed to polypharmacy because of multiple chronic conditions.
  • Many risk factors for polypharmacy have been identified including age, race/ethnicity, sex, educational achievement level, health status, and number of chronic diseases.
  • OBJECTIVE: The objective of this study was to analyze each common disease in the elderly with respect to prescribed drugs and polypharmacy.
  • The number of drugs and prevalence of polypharmacy were hypertension, 5.2 (3.9 [51%]); hyperlipidemia, 5.6 (3.8 [58%]); gastric ulcer, 5.4 (3.8 [53%]); previous stroke, 5.8 (3.2 [61%]); reflux esophagitis, 5.6 (3.8 [40%]), diabetes mellitus, 5.6 (3.1 [54%]); malignancy, 4.1 (3.1 [37%]); osteoporosis, 5.4 (3.4 [45%]); angina pectoris, 5.7 (3.6 [42%]); congestive heart failure, 6.1 (4.0 [60%]); chronic obstructive pulmonary disease, 5.0 (3.5 [53%]); dementia, 5.1 (3.2 [52%]); and depression, 7.0 (4.2 [73%]).
  • CONCLUSIONS: When assessing the risk of polypharmacy, physicians should carefully consider the type of any chronic disease.
  • Elderly patients with multiple diseases may be subjected to further polypharmacy.
  • [MeSH-major] Hospitalization / statistics & numerical data. Physician's Practice Patterns / statistics & numerical data. Polypharmacy. Prescription Drugs / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.
  • (PMID = 22387105.001).
  • [ISSN] 1876-7761
  • [Journal-full-title] The American journal of geriatric pharmacotherapy
  • [ISO-abbreviation] Am J Geriatr Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prescription Drugs
  •  go-up   go-down


46. |||||..... 52%  Boyda HN, Procyshyn RM, Tse L, Xu J, Jin CH, Wong D, Pang CC, Honer WG, Barr AM: Antipsychotic polypharmacy increases metabolic dysregulation in female rats. Exp Clin Psychopharmacol; 2013 Apr;21(2):164-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic polypharmacy increases metabolic dysregulation in female rats.
  • Antipsychotic polypharmacy refers to the clinical practice of treating a patient with two or more antipsychotic drugs concurrently.
  • There is abundant evidence in the clinical literature that treatment with antipsychotic polypharmacy is associated with an increased prevalence of drug side effects compared with monotherapy.
  • As these metabolic side effects have been accurately modeled in preclinical rodent paradigms using drug monotherapy, the goal of the present study was to determine the metabolic effects of antipsychotic polypharmacy using an established rodent model.
  • [MeSH-major] Antipsychotic Agents / adverse effects. Metabolism / drug effects. Polypharmacy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23356730.001).
  • [ISSN] 1936-2293
  • [Journal-full-title] Experimental and clinical psychopharmacology
  • [ISO-abbreviation] Exp Clin Psychopharmacol
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Insulin
  •  go-up   go-down


47. |||||..... 52%  Dovjak P: Tools in polypharmacy. Current evidence from observational and controlled studies. Z Gerontol Geriatr; 2012 Aug;45(6):468-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tools in polypharmacy. Current evidence from observational and controlled studies.
  • Increasing evidence in managing polypharmacy in the growing elderly population with a higher prevalence of multiple chronic disease is the basis for this paper.
  • Risk factors, the prevalence of polypharmacy, and the impact on health issues will be shown by analyzing the recent literature.
  • Based on intervention trials, several tools in polypharmacy have emerged as practical guides for clinical practice or for the geriatric ward to solve this problem.
  • [MeSH-major] Algorithms. Drug Interactions. Drug-Related Side Effects and Adverse Reactions / epidemiology. Evidence-Based Medicine. Inappropriate Prescribing / prevention & control. Inappropriate Prescribing / statistics & numerical data. Polypharmacy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22767400.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. |||||..... 52%  Barnett SR: Polypharmacy and perioperative medications in the elderly. Anesthesiol Clin; 2009 Sep;27(3):377-89, table of contents
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy and perioperative medications in the elderly.
  • Polypharmacy is a significant and complex problem affecting more than 40% of the geriatric population.
  • [MeSH-major] Anesthesia. Perioperative Care. Polypharmacy

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825482.001).
  • [ISSN] 1932-2275
  • [Journal-full-title] Anesthesiology clinics
  • [ISO-abbreviation] Anesthesiol Clin
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nonprescription Drugs; 0 / Plant Preparations
  • [Number-of-references] 31
  •  go-up   go-down


49. |||||..... 51%  Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC: Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev; 2012;5:CD008165
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions to improve the appropriate use of polypharmacy for older people.
  • BACKGROUND: Inappropriate polypharmacy is a particular concern in older people and is associated with negative health outcomes.
  • Choosing the best interventions to improve appropriate polypharmacy is a priority, hence there is growing interest in appropriate polypharmacy, where many medicines may be used to achieve better clinical outcomes for patients.
  • OBJECTIVES: This review sought to determine which interventions alone, or in combination, are effective in improving the appropriate use of polypharmacy and reducing medication-related problems in older people.
  • Search terms included polypharmacy, Beers criteria, medication appropriateness and inappropriate prescribing.
  • Eligible studies described interventions affecting prescribing aimed at improving appropriate polypharmacy in people aged 65 years and older where a validated measure of appropriateness was used (e.g.
  • AUTHORS' CONCLUSIONS: It is unclear if interventions to improve appropriate polypharmacy, such as pharmaceutical care, resulted in a clinically significant improvement; however, they appear beneficial in terms of reducing inappropriate prescribing and medication-related problems.
  • [MeSH-major] Medication Therapy Management. Polypharmacy. Quality Improvement

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22592727.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


50. |||||..... 51%  Gleason LJ, Luque AE, Shah K: Polypharmacy in the HIV-infected older adult population. Clin Interv Aging; 2013;8:749-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypharmacy in the HIV-infected older adult population.
  • Older HIV-infected patients are particularly at risk for polypharmacy because they often have multiple comorbidities that require pharmacotherapy.
  • Overall, there is not much known with respect to both the impact of aging on medication use in HIV-infected individuals, and the potential for interactions with highly active antiretroviral therapy (HAART) and coadministered medications and its clinical consequences.
  • In this review, we aim to provide an overview of polypharmacy with a focus on its impact on the HIV-infected older adult population and to also provide some clinical considerations in this high-risk population.
  • [MeSH-major] Aging. HIV Infections / drug therapy. Polypharmacy
  • [MeSH-minor] Aged. Antiretroviral Therapy, Highly Active. Comorbidity. Drug Interactions. Humans. Inappropriate Prescribing. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacokinet. 2003;42(3):223-82 [12603174.001]
  • [Cites] JAMA. 2003 Mar 5;289(9):1107-16 [12622580.001]
  • [Cites] J Clin Pharmacol. 2003 Apr;43(4):414-22 [12723462.001]
  • [Cites] Clin Infect Dis. 2003 Sep 1;37(5):613-27 [12942391.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2716-24 [14662625.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S90-7 [14986280.001]
  • [Cites] Drug Metab Rev. 2009;41(2):67-76 [19514965.001]
  • [Cites] Addict Biol. 2009 Jul;14(3):321-7 [19523046.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):437-44 [19623694.001]
  • [Cites] Ann Pharmacother. 2009 Oct;43(10):1667-75 [19737997.001]
  • [Cites] Pharmacotherapy. 2009 Oct;29(10):1175-81 [19792991.001]
  • [Cites] J Infect Dis. 2010 Feb 1;201(3):318-30 [20039804.001]
  • [Cites] Clin Pharmacokinet. 2010 Mar;49(3):177-88 [20170206.001]
  • [Cites] Int J Clin Pharmacol Ther. 2010 Mar;48(3):192-9 [20197013.001]
  • [Cites] HIV Med. 2010 Jul 1;11(6):412-7 [20146733.001]
  • [Cites] Eur J Clin Pharmacol. 2010 Oct;66(10):977-85 [20697700.001]
  • [Cites] JAMA. 2010 Oct 13;304(14):1592-601 [20940385.001]
  • [Cites] J Clin Pharmacol. 2011 Feb;51(2):271-8 [20421512.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Oct;8(5):419-27 [21335295.001]
  • [Cites] Ann Intern Med. 2000 Jul 4;133(1):21-30 [10877736.001]
  • [Cites] Arch Intern Med. 2000 Jul 24;160(14):2129-34 [10904455.001]
  • [Cites] Urology. 2000 Nov 1;56(5 Suppl 1):3-6 [11074195.001]
  • [Cites] Clin Infect Dis. 2001 Jan;32(1):130-9 [11118392.001]
  • [Cites] J Am Geriatr Soc. 2001 Feb;49(2):200-9 [11207875.001]
  • [Cites] Am J Psychiatry. 2001 May;158(5):725-30 [11329393.001]
  • [Cites] Ann Pharmacother. 2001 Sep;35(9):1004-9 [11573845.001]
  • [Cites] J Intern Med. 2001 Oct;250(4):327-41 [11576320.001]
  • [Cites] Ther Drug Monit. 2001 Oct;23(5):553-5 [11591903.001]
  • [Cites] JAMA. 2001 Oct 10;286(14):1732-9 [11594898.001]
  • [Cites] AIDS. 2001 Oct 19;15(15):2001-10 [11600829.001]
  • [Cites] JAMA. 2001 Dec 12;286(22):2823-9 [11735757.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):573-80 [16284534.001]
  • [Cites] AIDS. 2006 Jun 26;20(10):1401-6 [16791014.001]
  • [Cites] J Am Geriatr Soc. 2006 Oct;54(10):1516-23 [17038068.001]
  • [Cites] AIDS. 2006 Nov 14;20(17):2165-74 [17086056.001]
  • [Cites] Clin Infect Dis. 2006 Dec 15;43(12):1603-11 [17109296.001]
  • [Cites] Clin Pharmacol Ther. 2007 Jan;81(1):69-75 [17186001.001]
  • [Cites] Health Psychol. 2007 Jan;26(1):40-9 [17209696.001]
  • [Cites] J Gen Intern Med. 2007 Jan;22(1):6-12 [17351835.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1283-8 [17227801.001]
  • [Cites] Med Care. 2007 May;45(5):472-6 [17446834.001]
  • [Cites] AIDS. 2007 May 31;21(9):1119-27 [17502722.001]
  • [Cites] HIV Med. 2007 Oct;8(7):457-64 [17760738.001]
  • [Cites] Pharmacotherapy. 2007 Oct;27(10):1379-86 [17896893.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Nov;51(11):4098-104 [17846135.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):445-9 [11744832.001]
  • [Cites] Arch Intern Med. 1974 Aug;134(2):219-23 [4843186.001]
  • [Cites] J Pharmacokinet Biopharm. 1975 Jun;3(3):181-92 [1159622.001]
  • [Cites] J Urol. 1984 Sep;132(3):474-9 [6206240.001]
  • [Cites] J Am Geriatr Soc. 1988 Feb;36(2):142-9 [3276767.001]
  • [Cites] Hepatology. 1988 Sep-Oct;8(5):1079-83 [3417228.001]
  • [Cites] Hepatology. 1989 Feb;9(2):297-301 [2643548.001]
  • [Cites] J Am Geriatr Soc. 1989 Aug;37(8):679-83 [2754151.001]
  • [Cites] Lancet. 1991 Aug 24;338(8765):469-71 [1714529.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1825-32 [1888249.001]
  • [Cites] J Clin Epidemiol. 1992 Oct;45(10):1045-51 [1474400.001]
  • [Cites] Am J Med. 1996 Apr;100(4):428-37 [8610730.001]
  • [Cites] AIDS. 1997 Feb;11(2):268-9 [9030388.001]
  • [Cites] Arch Intern Med. 1997 Jul 28;157(14):1531-6 [9236554.001]
  • [Cites] Endocrine. 2012 Jun;41(3):512-7 [22198528.001]
  • [Cites] J Infect Dis. 2012 Jun;205 Suppl 3:S391-8 [22577213.001]
  • [Cites] J Am Geriatr Soc. 2012 May;60(5):974-9 [22568508.001]
  • [Cites] J Clin Pharmacol. 2012 Jun;52(6):922-31 [21712498.001]
  • [Cites] AIDS. 2012 Jul 31;26 Suppl 1:S39-53 [22781176.001]
  • [Cites] Int J STD AIDS. 2012 Jul;23(7):520-1 [22844010.001]
  • [Cites] AIDS Res Hum Retroviruses. 2012 Sep;28(9):972-80 [22353022.001]
  • [Cites] Int J STD AIDS. 2012 Aug;23(8):546-52 [22930290.001]
  • [Cites] Ann Pharmacother. 2012 Sep;46(9):1188-92 [22872750.001]
  • [Cites] J Clin Pharmacol. 2012 Nov;52(11):1725-38 [22174437.001]
  • [Cites] Curr Med Res Opin. 2013 Jan;29(1):1-12 [23136913.001]
  • [Cites] Curr Drug Metab. 2013 Feb;14(2):265-9 [23140258.001]
  • [Cites] Pharmacotherapy. 2013 May;33(5):e85-6 [23065869.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):337-44 [11790213.001]
  • [Cites] Clin Infect Dis. 2002 Apr 15;34(8):1143-5 [11915005.001]
  • [Cites] Drug Saf. 2002;25(4):263-86 [11994029.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):187-90 [12045681.001]
  • [Cites] Ann Pharmacother. 2002 Nov;36(11):1675-81 [12398558.001]
  • [Cites] Clin Infect Dis. 2002 Nov 15;35(10):1238-43 [12410484.001]
  • [Cites] J Am Soc Nephrol. 2007 Nov;18(11):2968-74 [17942954.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Dec;5(4):345-51 [18179993.001]
  • [Cites] Clin Infect Dis. 2007 Dec 15;45(12):1593-601 [18190322.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):481-7 [18301060.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1922-8 [18430911.001]
  • [Cites] J Behav Med. 2008 Jun;31(3):213-24 [18202907.001]
  • [Cites] Proc West Pharmacol Soc. 2007;50:16-20 [18605223.001]
  • [Cites] Clin Infect Dis. 2008 Aug 15;47(4):542-53 [18627268.001]
  • [Cites] Lancet. 2008 Jul 26;372(9635):293-9 [18657708.001]
  • [Cites] Clin Interv Aging. 2008;3(2):383-9 [18686760.001]
  • [Cites] J Clin Pharmacol. 2008 Oct;48(10):1212-25 [18812611.001]
  • [Cites] J Endocrinol Invest. 2008 Sep;31(9):799-808 [18997493.001]
  • [Cites] Geriatrics. 2008 Dec;63(12):6-12 [19061274.001]
  • [Cites] Drugs Aging. 2009;26(2):123-33 [19220069.001]
  • [Cites] Med Care. 2009 Mar;47(3):370-3 [19194338.001]
  • [Cites] Ann Pharmacother. 2009 Feb;43(2):322-8 [19196837.001]
  • [Cites] Arch Intern Med. 2011 Feb 28;171(4):300-5 [21357804.001]
  • [Cites] AIDS. 2011 Mar 27;25(6):F7-12 [21412057.001]
  • [Cites] Clin Infect Dis. 2011 Apr 15;52(8):1061-8 [21398272.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):429-42 [21663837.001]
  • [Cites] Ann Pharmacother. 2011 Jun;45(6):823-4 [21558486.001]
  • [Cites] J Antimicrob Chemother. 2011 Sep;66(9):2107-11 [21680580.001]
  • [Cites] AIDS Patient Care STDS. 2011 Sep;25(9):509-15 [21770762.001]
  • [Cites] AIDS. 2011 Sep 24;25(15):1881-6 [21811136.001]
  • [Cites] Clin J Am Soc Nephrol. 2011 Nov;6(11):2634-41 [21885793.001]
  • [Cites] N Engl J Med. 2011 Nov 24;365(21):2002-12 [22111719.001]
  • [Cites] Lancet Oncol. 2011 Dec;12(13):1249-57 [21741307.001]
  • [Cites] AIDS. 2012 Apr 24;26(7):867-75 [22313955.001]
  • [Cites] J Am Geriatr Soc. 2012 Apr;60(4):616-31 [22376048.001]
  • [Cites] AIDS. 2004 Jan 1;18 Suppl 1:S19-25 [15075494.001]
  • [Cites] Drugs. 2004;64(10):1091-124 [15139788.001]
  • [Cites] Ageing Res Rev. 2004 Jan;3(1):31-54 [15164725.001]
  • [Cites] J Am Geriatr Soc. 2004 Aug;52(8):1349-54 [15271125.001]
  • [Cites] Arch Intern Med. 1997 Aug 11-25;157(15):1681-6 [9250229.001]
  • [Cites] Br J Clin Pharmacol. 1997 Aug;44(2):190-4 [9278209.001]
  • [Cites] BMJ. 1997 Oct 25;315(7115):1096-9 [9366745.001]
  • [Cites] Am J Psychiatry. 1998 Mar;155(3):367-72 [9501747.001]
  • [Cites] JAMA. 1998 Apr 15;279(15):1200-5 [9555760.001]
  • [Cites] Ann Pharmacother. 1998 Dec;32(12):1299-302 [9876810.001]
  • [Cites] J Gen Intern Med. 1999 Apr;14(4):249-54 [10203638.001]
  • [Cites] J Clin Psychopharmacol. 1999 Aug;19(4):293-6 [10440454.001]
  • [Cites] Ann Pharmacother. 2005 Jan;39(1):141-5 [15562140.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Feb;60(12):865-73 [15657782.001]
  • [Cites] JAMA. 2005 Mar 16;293(11):1348-58 [15769968.001]
  • [Cites] AIDS. 2005 Apr 29;19(7):641-52 [15821390.001]
  • [Cites] Clin Infect Dis. 2005 Jun 1;40(11):1559-85 [15889353.001]
  • [Cites] AIDS. 2005 Jun 10;19(9):953-60 [15905677.001]
  • [Cites] JAAPA. 2005 May;18(5):32-7 [15918615.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):307-12 [15980690.001]
  • [Cites] Treat Endocrinol. 2004;3(4):217-21 [16026104.001]
  • [Cites] N Engl J Med. 2005 Aug 4;353(5):487-97 [16079372.001]
  • [Cites] Clin Pharmacol Ther. 2005 Aug;78(2):143-53 [16084849.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):716-24 [16091574.001]
  • [Cites] Arch Intern Med. 2005 Sep 12;165(16):1882-8 [16157833.001]
  • (PMID = 23818773.001).
  • [ISSN] 1178-1998
  • [Journal-full-title] Clinical interventions in aging
  • [ISO-abbreviation] Clin Interv Aging
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024136; United States / NIAID NIH HHS / AI / P30 AI078498; United States / NCATS NIH HHS / TR / UL1 TR000042
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3693722
  • [Keywords] NOTNLM ; HIV / older adults / polypharmacy
  •  go-up   go-down


top


2. Definitions


3. Related RMF webpages


terms of use | advertising programs | contact us
© 2014 RecentMedicalFindings


Connect with the


RMF


audience;




Post your ad here!